WEST PHARMACEUTICAL SERVICES INC
For the period ended Mar 31, 2026. Filed Apr 23, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 23, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. OTHER INFORMATION
Rule 10b5-1 Trading Plans
During the three months ended March 31, 2026, no director or officer (as defined in Rule 16a-1(f) promulgated under the Exchange Act) of the Company adopted orterminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the period covered by this Report, except as follows:
On March 11, 2026, Eric M. Green, our President and Chief Executive Officer and Chair of the Board of Directors, adopted a Rule 10b5-1 trading arrangement, which is intended to satisfy the affirmative defense of Rule 10b5-1(c) with respect to options that will be expiring on February 21, 2027. The Rule 10b5-1 trading arrangement provides for the acquisition by option exercise of 83,616 shares of our common stock on February 4, 2027 and then sold by February 19, 2027, in accordance with the terms specified in the trading arrangement. Actual sale transactions will be disclosed publicly in filings with the SEC in accordance with applicable securities laws, rules and regulations.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.